Primus In News
Pharma stocks rise as US considers exempting generics from tariffs
09-10-2025
Shravan Shetty, Managing Director, Primus Partners, highlighted the importance of India's $10 billion generic drug exports to the US for domestic pharma companies. He emphasized that potential tariff exemptions on generics would protect this vital revenue stream. Additionally, he said the recent market recovery reflects a rebound from previous declines, with further growth likely as generics gain traction in the US due to widening price gaps with branded drugs.
Explore Related Insights
- India's Urban Population to Reach 600 Million by 2036: Primus Partners Report
- Boeing deliveries will taper off by year-end. What happens to Akasa and AI Express?
- Choosing The Right Real Estate Developer Is No Cakewalk. Here Is An Easy Guide
- Auto Industry Retail Sales Off to Promising Start in 2025, Up 7% in Jan: FADA
